Mayo Clinic scientists have developed a groundbreaking method to estimate an individual’s risk of developing memory and cognitive decline decades before Alzheimer’s symptoms appear. This innovative tool, published in The Lancet Neurology, uses brain scans, genetics, and medical records from over 5,800 adults to predict both 10-year and lifetime risk of cognitive decline, marking a significant step in early detection and treatment strategies.
Research led by Dr. Clifford Jack Jr. analyzed data from the Mayo Clinic Study of Aging, a long-term tracking effort of thousands of residents. The team incorporated age, sex, and genetic factors like the APOE ε4 gene to build a predictive model. Their findings suggest that higher amyloid levels in the brain are strongly correlated with increased lifetime and 10-year risks of developing memory problems and cognitive decline.
Despite its promising potential, the study acknowledges limitations such as its focus on older white adults and reliance on expensive brain scans. However, researchers envision future versions that may include simpler methods like blood tests for amyloid or other biomarkers. The study, funded by the National Institute on Aging and other foundations, aims to advance personalized prevention strategies for Alzheimer’s disease.